Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.72B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.47M
Average 1.11M
Income Statement
Follow revenue through to earnings.
Revenue
$54.03M
FY 2025 · Annual
+48.0% YoYOperating Income
-$472.13M
FY 2025 · Annual
Net Income
-$412.78M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 14.24M | 26.82M | 36.5M | 54.03M |
| Cost of Revenue | 18.78M | 1.7M | 9.5M | 4.17M | 11.52M |
| Gross Profit | (18.78M) | 12.54M | 17.32M | 32.33M | 42.51M |
| Gross Margin | — | 88.0% | 64.6% | 88.6% | 78.7% |
| Research & Development | 256.97M | 279.91M | 288.9M | 301.29M | 334.36M |
| Selling, General & Admin | 121.45M | 121.67M | 119.9M | 156.78M | 180.28M |
| Operating Expenses | 359.64M | 401.58M | 408.81M | 458.07M | 514.64M |
| Depreciation & Amortization | 18.78M | 8.56M | 6.62M | 5.65M | 5.18M |
| EBITDA | (337.73M) | (223.24M) | (345.47M) | 723.62M | (408.62M) |
| EBITDA Margin | — | -1567.7% | -1287.9% | 1982.6% | -756.3% |
| Operating Income | (378.42M) | (389.05M) | (391.49M) | (425.74M) | (472.13M) |
| Operating Margin | — | -2732.1% | -1459.5% | -1166.5% | -873.9% |
| Interest Income | 836K | 12.79M | 33.34M | 48.08M | 56.38M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 21.91M | 157.25M | 39.4M | 1.14B | 58.34M |
| Income Before Tax | (356.51M) | (231.8M) | (352.09M) | 717.97M | (413.8M) |
| Pre-Tax Margin | — | -1627.8% | -1312.6% | 1967.1% | -765.9% |
| Income Tax Expense | 0 | 0 | 0 | 44.24M | (1.02M) |
| Net Income | 1.6B | (231.8M) | (352.09M) | 673.73M | (412.78M) |
| Net Margin | — | -1627.8% | -1312.6% | 1845.9% | -764.0% |
| EPS (Basic) | (6.36) | (4.23) | (6.33) | 11.86 | (7.12) |
| EPS (Diluted) | (6.36) | (4.23) | (6.33) | 11.64 | (7.12) |
| 60.45M | 54.79M | 55.65M | 56.81M | 57.97M | |
| 60.45M | 54.79M | 55.65M | 57.89M | 57.97M |
AGIO Earnings Waterfall · TTM
NASDAQ:AGIO · Revenue to Net Income
Key Ratios
Analysis
$66.0M of revenue converted into -$422.6M of net income for the selected period. Gross margin is 81.0% and net margin is -680.3%, showing how much revenue survives after costs and taxes. EPS is $-7.25, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 23, 2026 |
How much revenue does AGIO generate?
Agios Pharmaceuticals, Inc. (AGIO) reported $54.03M of revenue in fiscal 2025.
Is AGIO profitable?
Agios Pharmaceuticals, Inc. (AGIO) reported -$412.78M of net income, with a net margin of -764.0%.
Continue the stock analysis
Jump to another research area for this company.